Medicinal Chemistry News and Research

RSS

TACTIC project aims to uncover genetic causes of cancer and develop targeted therapies

Investigating the genetic causes of cancer and fighting them with new drugs: To this end, German Cancer Aid is funding the TACTIC project until 2028 with 11.8 million euros.

16 Nov 2023

Novel cancer immunotherapy compound degrades an enzyme found in cancer cells and T cells

Researchers in Purdue University's College of Pharmacy are leveraging the dual roles played by an enzyme found in both cancer cells and T cells to create a novel cancer immunotherapy compound.

14 Nov 2023

New prodrug approach enhances drug delivery to brain cells

A new study from the University of Eastern Finland shows that the delivery of drugs into the brain, and especially into glial cells, can be enhanced with prodrugs that temporarily incorporate thyroxine or a thyroxine-like molecule.

8 Nov 2023

The development of a machine-learned scoring function of human preference in the context of early drug discovery campaigns

In a recent study published in Nature Communications, researchers developed a scoring mechanism based on artificial intelligence for early drug discovery campaigns that might be utilized for compound prioritizing, motif rationalization, and biased drug design.

1 Nov 2023

UQ's drug discovery facility opens to researchers nationwide after $1.9M funding injection

The University of Queensland's small molecule drug discovery facility will open its doors to researchers from across Australia for the first time thanks to a National Collaborative Research Infrastructure Strategy (NCRIS) funding injection.

30 Oct 2023

MuTaLig: A multi-target paradigm for innovative drug discoveries

Everyone at some point in their life may need to take medication to treat an illness or disease. By finding new and better ways to create drugs, the COST Action Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig) helped improve the effectiveness and safety of the medications, which can ultimately benefit people's health and well-being.

19 Oct 2023

HKU-developed antibiotic drug to enter clinical trials in Mainland China

A new antibiotic drug developed by a research team led by Professor Li Xuechen from the Department of Chemistry at The University of Hong Kong (HKU) has recently gained approval from the authorities to undergo clinical trials in the Mainland.

10 Oct 2023

Optibrium releases powerful metabolism prediction capability in next generation StarDrop software

Optibrium, a leading developer of software and AI solutions for drug discovery, today launched the latest version of its drug discovery platform, StarDrop.

From Optibrium Ltd. 2 Oct 2023

UTHSC study aims to develop a new way to treat ischemic stroke

A study at the University of Tennessee Health Science Center aims to develop a new way to treat ischemic stroke, a leading cause of death in adults worldwide.

8 Sep 2023

Texas Heart Institute receives $1.14 million grant to develop first-in-class drug to treat cardiovascular disease

The National Heart, Lung, and Blood Institute (NHLBI) recently awarded The Texas Heart Institute (THI) a two-year, $1.14 million grant to develop a novel, first-in-class drug to treat cardiovascular disease (CVD) as a significant improvement to current treatment regimens -; specifically for adverse events arising from atherosclerosis.

22 Aug 2023

Proxalutamide shows promise as potential COVID-19 treatment

At the outset of the COVID pandemic, men appeared to suffer higher rates of severe illness and death, leading researchers to suspect a link between androgen receptors-;which bind to hormones like testosterone--and SARS-CoV-2 viral infection.

18 Aug 2023

Insilico Medicine uses AI to discover novel SIK2 inhibitors

Insilico Medicine ("Insilico"), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.

2 Aug 2023

Two new compounds can block cancer cell’s escape route

Cancer cells are capable of escaping chemotherapy and radiotherapy by activating a signaling pathway that prevents them from dying.

27 Jul 2023

MD Anderson and Nexo Therapeutics partner to advance new cancer therapies against previously undruggable targets

The University of Texas MD Anderson Cancer Center and Nexo Therapeutics today announced a multi-year strategic collaboration that aligns the innovative technology and capabilities of each organization at the earliest stages of drug discovery and development to rapidly advance impactful new cancer therapies against previously undruggable targets.

26 Jul 2023

New compound shows promise in stopping breast cancer metastasis

Researchers from the University of Liverpool have created a biomedical compound that has the potential to stop the spread of breast cancer. A recently published paper details these early findings.

21 Jul 2023

New mRNA-based malaria vaccine shows promise in preclinical trials

Trans-Tasman research collaborators from Te Herenga Waka-; Victoria University of Wellington's Ferrier Research Institute and the Malaghan Institute of Medical Research in New Zealand, and the Peter Doherty Institute for Infection and Immunity in Australia have developed an mRNA-based vaccine that can effectively target and stimulate protective immune cell responses against the malaria-causing parasite Plasmodium in preclinical models.

20 Jul 2023

Fentanyl overdose reversal: New hope on the horizon

According to the Centers for Disease Control, 100,000 Americans die each year from an overdose, most due to the use of synthetic opiates like fentanyl. While naloxone, currently the only an antidote for opiate overdose, has become more common, it is less effective against fentanyl-class synthetic opioids.

18 Jul 2023

PhoreMost appoints Professor Peter Parker and Dr Jason Imbriglio to Scientific Advisory Board

PhoreMost Ltd. announced Professor Peter Parker and Dr Jason Imbriglio as members of its Scientific Advisory Board (SAB).

From PhoreMost 17 Jul 2023

Amplified Sciences secures $400,000 grant to develop pancreatic cancer diagnostic test

Health care providers and their patients could know with greater confidence whether pancreatic cysts are benign or potentially malignant, and if surgery is required to remove them, by using a new diagnostic test currently in development.

12 Jul 2023

Stanford and Intonation partner to develop new treatments for neuroendocrine tumors

Stanford University's Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.

23 Jun 2023